Results 1 to 10 of about 433,882 (351)

Landscape of inflammatory bowel disease in Singapore [PDF]

open access: yesIntestinal Research, 2022
Inflammatory bowel disease (IBD), primarily Crohn’s disease and ulcerative colitis, had been widely recognized to affect the Western population. However, the notable rise in prevalence of IBD in Asia, including Singapore, had garnered much attention to ...
Daren Low   +3 more
doaj   +1 more source

Zinc Protoporphyrin Is a Reliable Marker of Functional Iron Deficiency in Patients with Inflammatory Bowel Disease

open access: yesDiagnostics, 2021
Iron deficiency (ID) is a common manifestation of inflammatory bowel disease (IBD), arising primarily due to chronic inflammation and/or blood loss. There is no gold standard for ID diagnosis, which is often complicated by concomitant inflammation.
Eleni Leventi   +4 more
doaj   +1 more source

Flipside of the Coin: Iron Deficiency and Colorectal Cancer

open access: yesFrontiers in Immunology, 2021
Iron deficiency, with or without anemia, is the most frequent hematological manifestation in individuals with cancer, and is especially common in patients with colorectal cancer.
Aysegül Aksan   +11 more
doaj   +1 more source

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis [PDF]

open access: yesIntestinal Research, 2021
Background/Aims Infliximab (IFX) has proven effective as rescue therapy in steroid-refractory acute severe ulcerative colitis (ASUC), however, the long-term real-world data are scarce.
Shin Ju Oh   +10 more
doaj   +1 more source

Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management

open access: yesFrontiers in Medicine, 2022
In recent years, immunotherapy has become an important pillar of cancer treatment, with high response rates regardless of tumor histology or baseline mutations, sometime in patients without any alternative of treatment.
Virginia Robles-Alonso   +3 more
doaj   +1 more source

Anti-NMDAR encephalitis in Crohn’s disease undergoing long-term infliximab treatment: A case report

open access: yesFrontiers in Immunology, 2022
Infliximab, a chimeric monoclonal antibody against anti-tumor necrosis factor-α (TNF-α), has revolutionized the management of inflammatory bowel disease. However, a recent nested case-control study showed that anti-TNF-α therapy exposure in patients with
Shin Ju Oh   +3 more
doaj   +1 more source

When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest

open access: yesBMC Medical Ethics, 2019
Background Much like academic-industry partnerships, industry financial support of patient advocacy organizations (PAOs) has become very common in recent years.
Orna Ehrlich   +3 more
doaj   +1 more source

Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis

open access: yesCells, 2020
PNAd and MAdCAM-1 addressins on venules are of importance in T-cell homing and potential therapeutic targets in ulcerative colitis (UC). Normally, PNAd+ high endothelial venules (HEVs) are only present in lymphoid organs, whereas small numbers of MAdCAM ...
Britt Roosenboom   +10 more
doaj   +1 more source

The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe

open access: yesBMC Gastroenterology, 2021
Background Ulcerative colitis (UC) is an inflammatory bowel disease with increasing prevalence worldwide. Current treatment strategies place considerable economic and humanistic burdens on patients.
Leonardo Ruiz-Casas   +14 more
doaj   +1 more source

Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models [PDF]

open access: yesIntestinal Research, 2020
The specific pathogenesis underlining inflammatory bowel disease (IBD) is very complicated, and it is further more difficult to clearly explain the pathophysiology of 2 major forms of IBD, Crohn’s disease (CD) and ulcerative colitis (UC), and both ...
Emiko Mizoguchi   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy